Senhwa Biosciences, Inc.

Novartis Ag

Novartis Vaccines & Diagnostics, Gmbh

Trilogy Therapeutics, Inc.

Honeywell International Inc.

David M Ryckman

Eric Harwood

Shuguang Zhu

Iching G Yu

Mustapha Haddach

Fabrice Pierre

Suchitra Ravula

Nicholas Brian Raffaele

Joe Anh Tran

Xiao Shang

Collin F Regan

Joyce Chou

Daniel J Poon

Augustus O Okhamafe

David Andrew Siesel

Michael Schwaebe

Timothy D Machajewski

Marion Wiesmann

Hshiou-ting Liu

Teresa E Pick

Carla C Heise

Shaopei Cai

Mingbao Zhang

Rampurna Gullapalli

Danlin Gu

Guohua Chen

Gabriel Galvin

Martin Dimitroff

Bridget R Miller

Brady S Stillwell

Tyson Swiftney

Brian Diaz

Jonathan P Van Dyck

Nicholas B Raffaele

Joe A Tran

Compositions and corresponding methods for the treatment and/or prevention of a fungal infection in the pulmonary system of a subject in need thereof with caspofungin or a derivative thereof are disclosed herein.

Caspofungin compositions for inhalation

The present invention includes crystalline forms of 2-(4-Methyl-[1,4]diazepan-1-yl)-5-oxo-5H-7-thia-1,11b-diaza-benzo[c]fluorene-6-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide and crystalline forms of salts and/or solvates of 2-(4-Methyl-[1,4]diazepan-1-yl)-5-oxo-5H-7-thia-1,11b-diaza-benzo[c]fluorene-6-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide. Furthermore, the present invention provides compositions comprising the crystalline forms and therapeutic use of the crystalline forms and the compositions thereof.

Crystalline forms of quinolone analogs and their salts

Methods for the treatment and/or prevention of a fungal infection in the pulmonary system of a subject in need thereof with caspofungin or a derivative thereof are disclosed herein.

Methods of treating lung infection with caspofungin

The invention provides compounds that inhibit protein kinase CK2 activity (CK2 activity), and compositions containing such compounds. These compounds and compositions are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and have the following general formula: 

Pyrazolopyrimidines and related heterocycles as CK2 inhibitors

The present invention relates to novel crystalline polymorphic salt forms of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid, processes for the preparation thereof, compositions thereof and their use in methods of treatment and prevention of conditions mediated by casein kinase (CK) and/or poly(ADP-ribose)polymerase (PARP).

Polymorphs and salts of a kinase inhibitor

The present invention relates to non-hydrate crystalline forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts, solid pharmaceutical formulations containing the same and methods of use. The present invention also relates to crystalline hydrates of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-l-yl)-lH-benzimidazol-2-yl]-lH-quinolin-2-one lactic acid salts, pharmaceutical formulations containing the same and methods of use related thereto. The present invention further relates to crystalline solvates of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-l-yl)-lH-benzimidazol-2-yl]-lH-quinolin-2-one lactic acid salts.

Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts

A method for synthesizing a heterocyclic compound includes: reacting 1-methylpiperazine with 5-chloro-2-nitroaniline at an internal temperature sufficient to provide a compound of Formula VIH The 1-methylpiperazine and the 5-chloro-2-nitroaniline are reacted in a solvent that comprises water in an amount greater than 50 percent by volume based on the amount of the solvent and/or are reacted in a solvent that comprises an organic solvent component that has a boiling point of greater than 100&#xb0; C. at atmospheric pressure. 

Methods for synthesizing heterocyclic compounds

Methods of inhibiting fibroblast growth factor receptor 3 and treating various conditions mediated by fibroblast growth factor receptor 3 are provided that include administering to a subject a compound of Structure I, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I have the following structure where and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting fibroblast growth factor receptor 3 and for use in treating conditions mediated by fibroblast growth factor receptor 3 such as multiple myeloma. 

Inhibition of FGFR3 and treatment of multiple myeloma

Methods for preparing new substituted benzimidazole compounds having formula (I) useful for treating kinase mediated disorders are provided wherein R, R, R, R, a, b, and c are defined herein 

Substituted benzimidazoles and methods of preparation

Hydroxythiol grignard reaction synthesis

Growing community of inventors

San Diego, CA, United States of America

David M Ryckman